Morgan Stanley Maintains Overweight on Dyne Therapeutics, Raises Price Target to $50
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and raises the price target from $46 to $50.
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and raises the price target from $46 to $50.